IOMERVU Approval Tests Sterile Injectable Compliance Across Indications

Bracco Diagnostics, Inc. secured FDA approval for IOMERVU (iomeprol) on November 27, 2024, a radiographic contrast agent cleared across a broad range of imaging indications spanning arteriography and CT procedures in both adult and pediatric populations. For QA directors and regulatory affairs leads managing sterile injectables portfolios, the multi-indication scope of this submission signals the increasing complexity regulators expect manufacturers to address within a single NDA package, with distinct dosing regimens, patient populations, and route-of-administration variables each carrying their own process validation and sterility assurance implications under 21 CFR Part 211.

IOMERVU is administered intra-arterially or intravenously and is indicated for cerebral, visceral, peripheral, and coronary arteriography, aortography, intra-arterial digital subtraction angiography, CT of the head and body, CT angiography, coronary CT angiography, and CT urography. The breadth of approved indications across two distinct administration routes requires manufacturers to demonstrate container-closure integrity and formulation stability across variable clinical use conditions, a challenge that compounds quality system demands under ICH Q10 frameworks.

The FDA based its approval on evidence from 13 clinical trials enrolling 1,222 adult patients across 67 sites in the United States, Italy, Germany, and Israel. Safety data drew from a broader pool of 4,804 patients receiving varying doses depending on indication and imaging procedure. Studies 1 through 9 evaluated image quality for arteriography and CT procedures, while Studies 10 through 13 assessed detection of abnormal arteries against standard imaging comparators. The divergence between efficacy and safety population sizes reflects the use of separate analytical pools, a regulatory design consideration that specialty injectable manufacturers should account for when structuring their own clinical and CMC submissions.

For plant heads overseeing sterile manufacturing lines, the IOMERVU dossier illustrates how contrast media submissions can require parallel validation strategies for intra-arterial and intravenous presentations, each with distinct extractables and leachables profiles and fill-volume considerations. Pediatric inclusion further extends the regulatory surface area, requiring age-appropriate dosing evidence that feeds back into batch record design and label controls. Specialty injectable manufacturers benchmarking their own regulatory strategies against approved contrast agent submissions will find the IOMERVU package a relevant reference point for multi-indication sterile product development.

Source: FDA Drug Trials Snapshots, IOMERVU, published April 29, 2026. Refer to the IOMERVU Prescribing Information for all approved conditions of use.